DDMAC enforcement letters skyrocket

Share this article:
As new resources come into FDA's Division of Drug Marketing, Advertising and Commissions, it reports that it has exceeded last year's totals for issuing warning and untitled letters sent to pharmaceutical marketers for violating agency advertising and promotion regulations.

Through August 30, according to division director Thomas Abrams, it had sent 45 such letters, four more than the total for 2009 and comfortably more than double the 21 sent the year before.

The increase is a continuation of FDA commissioner Margaret Hamburg's enforcement escalation initiative that she ordered a year ago, Abrams said.

The most common violations cited by the agency are: omission and minimization of risk information, unsubstantiated claims of efficacy or safety, unsubstantiated comparative claims, promotion of unapproved uses of drugs. The number of promotional pieces submitted to DDMAC last year spiked 8% to 76,631, according to DDMAC staff. The percentage increase was twice as high from 2008 when there was a 4% increase.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?